PALB2 and cancer: Of patients who did not have a positive family history of any cancer (n = 487), 57 deleterious variants were detected in 54 patients, including BRCA2 (40.4%, 23/57), BRCA1 (22.8%, 13/57), PALB2 (10.5%, 6/57), NBN (5.3%, 3/57), MRE11A (5.3%, 3/57) and other genes (15.8%, 9/57).